View Item 

Show simple item record

Vigilancia del colangiocarcinoma en pacientes con colangitis esclerosante primaria: ¿es efectiva y está justificada?
dc.contributor.authorRazumilava, Nataliya
dc.contributor.authorGores, Gregory J.
dc.date.accessioned2017-01-06T20:46:06Z
dc.date.available2018-01-08T19:47:52Zen
dc.date.issued2016-11
dc.identifier.citationRazumilava, Nataliya; Gores, Gregory J. (2016). "Vigilancia del colangiocarcinoma en pacientes con colangitis esclerosante primaria: ¿es efectiva y está justificada?." Clinical Liver Disease 8(S1): S20-S24.
dc.identifier.issn2046-2484
dc.identifier.issn2046-2484
dc.identifier.urihttps://hdl.handle.net/2027.42/134814
dc.publisherWorld Bank Publications
dc.publisherWiley Periodicals, Inc.
dc.titleVigilancia del colangiocarcinoma en pacientes con colangitis esclerosante primaria: ¿es efectiva y está justificada?
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelGastroenterology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/134814/1/cld602.pdf
dc.identifier.doi10.1002/cld.602
dc.identifier.sourceClinical Liver Disease
dc.identifier.citedreferenceSullivan T, Sullivan R, Ginsburg OM. Screening for cancer: considerations for low‐ and middle‐income countries. In: Gelband H, Jha P, Sankaranarayanan R, Horton S, eds. Cancer: Disease Control Priorities. Vol. 3. 3rd ed. World Bank Publications, Washington, DC; 2015.
dc.identifier.citedreferenceRazumilava N, Gores GJ, Lindor KD. Cancer surveillance in patients with primary sclerosing cholangitis. Hepatology 2011; 54: 1842 – 1852.
dc.identifier.citedreferenceSingal AK, Stanca CM, Clark V, Dixon L, Levy C, Odin JA, et al. Natural history of small duct primary sclerosing cholangitis: a case series with review of the literature. Hepatol Int 2011; 5: 808 – 813.
dc.identifier.citedreferenceClaessen MM, Vleggaar FP, Tytgat KM, Siersema PD, van Buuren HR. High lifetime risk of cancer in primary sclerosing cholangitis. J Hepatol 2009; 50: 158 – 164.
dc.identifier.citedreferenceChapman R, Fevery J, Kalloo A, Nagorney DM, Boberg KM, Shneider B, et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology 2010; 51: 660 – 678.
dc.identifier.citedreferenceEASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol. 2009; 51: 237 – 267.
dc.identifier.citedreferenceLindor KD, Kowdley KV, Harrison ME, American College of Gastroenterology. ACG Clinical Guideline: primary sclerosing cholangitis. Am J Gastroenterol 2015; 110: 646 – 659; quiz 660.
dc.identifier.citedreferenceGulamhusein AF, Eaton JE, Tabibian JH, Atkinson EJ, Juran BD, Lazaridis KN. Duration of inflammatory bowel disease is associated with increased risk of cholangiocarcinoma in patients with primary sclerosing cholangitis and IBD. Am J Gastroenterol 2016; 111: 705 – 711.
dc.identifier.citedreferenceRazumilava N, Gores GJ. Cholangiocarcinoma. Lancet 2014; 383: 2168 – 2179.
dc.identifier.citedreferenceBarr Fritcher EG, Voss JS, Jenkins SM, Lingineni RK, Clayton AC, Roberts LR, et al. Primary sclerosing cholangitis with equivocal cytology: fluorescence in situ hybridization and serum CA 19‐9 predict risk of malignancy. Cancer Cytopathol 2013; 121: 708 – 717.
dc.identifier.citedreferenceBonato G, Cristoferi L, Strazzabosco M, Fabris L. Malignancies in primary sclerosing cholangitis ‐ a continuing threat. Dig Dis 2015; 33 ( Suppl 2 ): 140 – 148.
dc.identifier.citedreferenceTrilianos P, Selaru F, Li Z, Gurakar A. Trends in pre‐liver transplant screening for cholangiocarcinoma among patients with primary sclerosing cholangitis. Digestion 2014; 89: 165 – 173.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
cld602.pdf
Size:
557.8KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.